Metabolic Monitoring for Patients Treated with Antipsychotic Medications
Authors:
Open Access
- 1 July 2006
- journal article
- review article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 51 (8) , 492-501
Abstract
Objectives: Metabolic side effects of antipsychotic treatment include weight gain, dyslipidemia and increased susceptibility to diabetes. Patients with schizophrenia have increased coronary heart disease mortality and reduced life expectancy. There is an urgent clinical need to monitor antipsychotic-treated patients for metabolic disturbance. Our objectives were to review published international monitoring guidelines, establish goals for metabolic monitoring, and make recommendations for practice. Method: We reviewed the major published consensus guidelines for metabolic monitoring of patients treated with antipsychotic medications and selectively reviewed practice guidelines for the management of diabetes, dyslipidemia, and hypertension. Results: Patients with serious mental illness have markedly elevated rates of metabolic disturbance and limited access to general medical care. Monitoring, but not necessarily medical treatment of metabolic disorder, falls within the scope of psychiatric practice and should include screening for metabolic disturbance as well as tracking the effects of antipsychotic treatment. In addition, psychiatrists and psychiatric services should work toward facilitating patients' access to medical care. There is considerable consensus in the published guidelines. Areas of dissent include which patients to monitor, the utility of glucose tolerance testing, and the point at which to consider switching antipsychotics. Conclusion: We encourage clinicians to adopt a structured system for conducting and recording metabolic monitoring and to develop collaborations with family physicians, diabetes specialists, dieticians, and recreation therapists to facilitate appropriate medical care for antipsychotic-treated patients.Keywords
This publication has 25 references indexed in Scilit:
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsSchizophrenia Research, 2005
- Association between antipsychotic drugs and diabetesDiabetes, Obesity and Metabolism, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK settingDiabetic Medicine, 2004
- Screening for Type 2 DiabetesDiabetes Care, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- The Cost-effectiveness of Screening for Type 2 DiabetesJAMA, 1998
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997